Wall St Journal

Surprising Fatty Liver Results Could Put Madrigal in Big Pharma’s Sights

breakingnow_w51jcqDecember 19, 2022

Better-than-expected results for company’s NASH treatment could rekindle big pharma interest in this disease area

Read the original article

Tags:

biology Biotechnology Content Types corporate Corporate/Industrial News development Factiva Filters general news Health healthcare Healthcare/Life Sciences heard on the street humanities industrial news life sciences Madrigal Pharmaceuticals MDGL medical treatments Medical Treatments/Procedures medications Pharmaceuticals political Political/General News procedures research Research/Development sciences Sciences/Humanities specialized drugs Specialized Drugs/Medications synd WSJ-PRO-WSJ.com

breakingnow_w51jcq

Previous PostGoldman doubles down on call for investors to shun industrials stocks despite their dazzling 4th-quarter performance
Next PostDespite Crypto Collapse, VCs Are Still Investing Billions In Blockchain Gaming - Bitcoin (BTC/USD), GameStop (NYSE:GME)

Leave a Reply Cancel Reply